NeoGenomics (NEO)
(Delayed Data from NSDQ)
$5.16 USD
+0.32 (6.61%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $5.17 +0.01 (0.19%) 7:58 PM ET
4-Sell of 5 4
C Value A Growth C Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, NeoGenomics, Inc. has a PEG ratio of 0.86 compared to the Medical - Biomedical and Genetics industry's PEG ratio of 1.85.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
NEO 5.16 +0.32(6.61%)
Will NEO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for NEO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NEO
Down 29.2% in 4 Weeks, Here's Why NeoGenomics (NEO) Looks Ripe for a Turnaround
NeoGenomics (NEO) Meets Q2 Earnings Estimates
NEO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Analysts Estimate Amicus Therapeutics (FOLD) to Report a Decline in Earnings: What to Look Out for
NeoGenomics (NEO) Reports Break-Even Earnings for Q1
Analysts Estimate GSK (GSK) to Report a Decline in Earnings: What to Look Out for
Other News for NEO
NeoGenomics (NEO) Stock Price Target Lowered by Morgan Stanley | NEO Stock News
NeoGenomics (NEO) Price Target Cut by Morgan Stanley amid Revenue Challenges
Peloton upgraded, Booking downgraded: Wall Street's top analyst calls
NeoGenomics price target lowered by $2 at Morgan Stanley, here's why
NeoGenomics Launches PanTracer LBx, Expanding Access to Comprehensive Genomic Profiling with ...